+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the safety and effects of Abrocitinib in adults with moderate to severe atopic dermatitis, a long-lasting skin condition that causes inflammation, redness, and irritation. This observational study aims to understand how Abrocitinib works in real-life clinical settings for patients aged 18 and older who do not have other medical conditions that would prevent them from taking the medication. All participants will take Abrocitinib as a daily tablet and may also use medicated topical treatments for their condition. The study lasts 24 months, during which participants will be monitored regularly. They will visit the study clinic approximately five times, about once every 4 to 6 months, to report their experiences and health status while using the medication. Throughout the study, researchers will assess participants using various measures such as skin condition scores, itching severity scales, and sleep quality assessments. They will also track treatment adherence, any changes in medication dosage, and any side effects. The main outcome focuses on the proportion of patients achieving clear or almost clear skin after 16 weeks, with ongoing evaluations through 24 months to monitor safety and effectiveness.

Age: 18Years +All Genders
30 locations
E

Actively Recruiting

Atopic dermatitis AD is a long-lasting inflammatory skin condition characterized by itching and recurring eczematous eruptions. Researchers are studying skin changes in patients with moderate-to-severe AD who are treated with nemolizumab, a humanized anti-IL-31 monoclonal antibody, to better understand how the skin structure changes during treatment. This research uses reflectance confocal microscopy RCM, a noninvasive technique that examines the epidermis and papillary dermis at a cellular level, to evaluate skin structure and inflammation. The study observes patients with moderate-to-severe AD who require systemic treatment with nemolizumab. Nemolizumab is being assessed for its impact on skin changes visible using RCM. The main goal is to measure the thickness of the affected skin at week 16 of treatment. Participants are monitored while receiving nemolizumab as part of their usual care. Participants will have their skin examined using RCM to observe structural and inflammatory changes during treatment. The research team will assess skin thickness at 16 weeks to evaluate treatment response. Eligible adults with moderate-to-severe AD will provide informed consent before joining. The study lasts until 2028, with follow-up assessments scheduled to understand skin modifications over time.

Age: 18Years +All Genders
1 location
P

Actively Recruiting

Researchers are investigating the best approach to treat patients with cutaneous squamous cell carcinoma CSCC who have a high risk of the cancer returning after surgery. This study compares two strategies adding radiation therapy after surgery called adjuvant radiotherapy versus closely monitoring patients without immediate additional treatment. The goal is to see if disease-free survival DFS, which means the time patients remain free from cancer recurrence, differs between these two approaches. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy starting within 8 to 12 weeks after surgery, delivering a total dose of 45 to 50 Gy to the area where the tumor was removed. Radiation may be given externally with high-energy photons or electrons, or through brachytherapy. The other group will undergo regular monitoring without additional treatment after surgery. Both groups will continue follow-up until cancer recurrence or death, with decisions for any further treatment left to the treating physician. Participants will be followed every 4 months for the first 2 years and then every 6 months thereafter. During visits, doctors will perform clinical exams, review any other treatments the patient is receiving, conduct imaging tests, and assess quality of life through questionnaires. The study will track outcomes such as disease-free survival, local and regional recurrence, metastatic recurrence, overall survival, treatment tolerance, and quality of life. Follow-up will continue until death or progression of disease, with assessments up to 36 months for many outcomes.

Age: 18Years +All GendersPhase 3
28 locations
R

Actively Recruiting

Plaque psoriasis is a chronic inflammatory skin condition that causes thick, red, and scaly patches. This research evaluates how treatment with risankizumab affects the quality of life in adults with moderate to severe plaque psoriasis in real-world clinical settings. About 700 participants prescribed risankizumab by their doctors according to local guidelines will be involved in this study. Participants will receive risankizumab as directed by their physicians based on routine care and local labeling. There are no additional treatments or study drugs provided beyond what is normally prescribed. The study is observational and follows participants for up to 2.5 years while they continue their usual treatment. During the study, participants will attend regular visits at hospitals or clinics as part of their standard care. Researchers will assess outcomes such as the proportion of participants achieving a Dermatology Life Quality Index DLQI score of 0 or 1 at 12 months. The study aims to understand the impact of risankizumab on quality of life with minimal extra burden to participants.

Age: 18Years +All Genders
84 locations
O

Actively Recruiting

Researchers are studying atopic dermatitis AD in adolescents and adults to better understand the unmet needs across this condition and to observe how systemic treatments work in real-world settings. This observational study aims to explore patients journeys, including factors like age, skin color, flare triggers, past treatment responses, comorbidities, and lesion characteristics. It involves multiple countries and diverse populations to capture a broad picture of treatment impacts over time. The study follows patients who begin or switch any systemic treatment for AD, such as biologics, oral Janus kinase inhibitors, cyclosporine, azathioprine, methotrexate, or mycophenolate mofetil, as prescribed by their doctors based on local guidelines. Researchers do not assign treatments but collect information on treatment choices and changes during standard care. This registry will track treatment sequences, interruptions, dose changes, and reasons for starting or stopping treatments over a five-year period. Participants will be followed for up to five years to monitor their treatment experience and disease progression. Data collection includes assessments of disease severity using tools like the Eczema Area and Severity Index EASI, body surface area affected, and global assessments of AD. Patient-reported outcomes such as itch, skin pain, sleep disturbance, quality of life, work productivity, and treatment satisfaction will also be recorded. Safety will be monitored through reports of adverse events. The study collects demographics, comorbid conditions, healthcare visits, and medication use to provide a comprehensive view of AD management in everyday care.

Age: 12Years +All Genders
82 locations